451 related articles for article (PubMed ID: 18464307)
1. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study.
Bérezné A; Ranque B; Valeyre D; Brauner M; Allanore Y; Launay D; Le Guern V; Kahn JE; Couderc LJ; Constans J; Cohen P; Mahr A; Pagnoux C; Hachulla E; Kahan A; Cabane J; Guillevin L; Mouthon L
J Rheumatol; 2008 Jun; 35(6):1064-72. PubMed ID: 18464307
[TBL] [Abstract][Full Text] [Related]
2. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.
Wanchu A; Suryanaryana BS; Sharma S; Sharma A; Bambery P
Int J Rheum Dis; 2009 Sep; 12(3):239-42. PubMed ID: 20374353
[TBL] [Abstract][Full Text] [Related]
3. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
[TBL] [Abstract][Full Text] [Related]
4. Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?
Bérezné A; Valeyre D; Ranque B; Guillevin L; Mouthon L
Ann N Y Acad Sci; 2007 Sep; 1110():271-84. PubMed ID: 17911442
[TBL] [Abstract][Full Text] [Related]
5. Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease.
Mittoo S; Wigley FM; Wise R; Xiao H; Hummers L
Arthritis Rheum; 2007 Dec; 56(12):4195-202. PubMed ID: 18050251
[TBL] [Abstract][Full Text] [Related]
6. Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders.
Iudici M; Cuomo G; Vettori S; Bocchino M; Sanduzzi Zamparelli A; Cappabianca S; Valentini G
Semin Arthritis Rheum; 2015 Feb; 44(4):437-44. PubMed ID: 25282395
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients.
Ribi C; Cohen P; Pagnoux C; Mahr A; Arène JP; Lauque D; Puéchal X; Letellier P; Delaval P; Cordier JF; Guillevin L;
Arthritis Rheum; 2008 Feb; 58(2):586-94. PubMed ID: 18240234
[TBL] [Abstract][Full Text] [Related]
8. Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function.
van den Hombergh WMT; Simons SO; Teesselink E; Knaapen-Hans HKA; van den Hoogen FHJ; Fransen J; Vonk MC
Clin Rheumatol; 2018 Oct; 37(10):2715-2722. PubMed ID: 29987427
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease.
Trad S; Amoura Z; Beigelman C; Haroche J; Costedoat N; Boutin le TH; Cacoub P; Frances C; Wechsler B; Grenier P; Piette JC
Arthritis Rheum; 2006 Jan; 54(1):184-91. PubMed ID: 16385514
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of patients with scleroderma interstitial lung disease treated with intravenous cyclophosphamide pulse therapy: a single-center experience.
Balbir-Gurman A; Yigla M; Guralnik L; Hardak E; Solomonov A; Rozin AP; Toledano K; Dagan A; Bishara R; Markovits D; Nahir MA; Braun-Moscovici Y
Isr Med Assoc J; 2015 Mar; 17(3):150-6. PubMed ID: 25946765
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of cyclophospamide in the treatment of interstitial lung disease associated with systemic sclerosis.
Espinosa G; Simeón CP; Plasín MÁ; Xaubet A; Muñoz X; Fonollosa V; Cervera R; Vilardell M
Arch Bronconeumol; 2011 May; 47(5):239-45. PubMed ID: 21458128
[TBL] [Abstract][Full Text] [Related]
12. Effect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study.
Furuya Y; Kuwana M
J Rheumatol; 2011 Oct; 38(10):2186-92. PubMed ID: 21885489
[TBL] [Abstract][Full Text] [Related]
13. Cyclophosphamide versus placebo in scleroderma lung disease.
Tashkin DP; Elashoff R; Clements PJ; Goldin J; Roth MD; Furst DE; Arriola E; Silver R; Strange C; Bolster M; Seibold JR; Riley DJ; Hsu VM; Varga J; Schraufnagel DE; Theodore A; Simms R; Wise R; Wigley F; White B; Steen V; Read C; Mayes M; Parsley E; Mubarak K; Connolly MK; Golden J; Olman M; Fessler B; Rothfield N; Metersky M;
N Engl J Med; 2006 Jun; 354(25):2655-66. PubMed ID: 16790698
[TBL] [Abstract][Full Text] [Related]
14. Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase.
Airò P; Danieli E; Rossi M; Frassi M; Cavazzana I; Scarsi M; Grottolo A; Franceschini F; Zambruni A
Clin Exp Rheumatol; 2007; 25(2):293-6. PubMed ID: 17543156
[TBL] [Abstract][Full Text] [Related]
15. [Comparative study between oral azathioprine and intravenous cyclophosphamide pulses in the treatment of idiopathic pulmonary fibrosis].
Roig V; Herrero A; Arroyo-Cózar M; Vielba D; Juarros S; Macías E
Arch Bronconeumol; 2010 Jan; 46(1):15-9. PubMed ID: 19879035
[TBL] [Abstract][Full Text] [Related]
16. Effect of Sequential Intravenous Pulse Cyclophosphamide-Azathioprine in Systemic Sclerosis-Interstitial Lung Disease: An Open-Label Study.
Kundu S; Paul S; Hariprasath K; Agarwal R; Ghosh S; Biswas D
Indian J Chest Dis Allied Sci; 2016; 58(1):7-10. PubMed ID: 28368564
[TBL] [Abstract][Full Text] [Related]
17. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis.
Colaci M; Sebastiani M; Giuggioli D; Manfredi A; Spagnolo P; Luppi F; Richeldi L; Ferri C
Scand J Rheumatol; 2010 Mar; 39(2):155-9. PubMed ID: 20059446
[TBL] [Abstract][Full Text] [Related]
18. Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis.
Apras S; Ertenli I; Ozbalkan Z; Kiraz S; Ozturk MA; Haznedaroglu IC; Cobankara V; Pay S; Calguneri M
Arthritis Rheum; 2003 Aug; 48(8):2256-61. PubMed ID: 12905480
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis.
Kameda H; Nagasawa H; Ogawa H; Sekiguchi N; Takei H; Tokuhira M; Amano K; Takeuchi T
J Rheumatol; 2005 Sep; 32(9):1719-26. PubMed ID: 16142867
[TBL] [Abstract][Full Text] [Related]
20. Systemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement-a retrospective study.
Poormoghim H; Rezaei N; Sheidaie Z; Almasi AR; Moradi-Lakeh M; Almasi S; Andalib E
Rheumatol Int; 2014 Dec; 34(12):1691-9. PubMed ID: 24801572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
